Published in Am J Pathol on October 01, 1994
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol (2003) 2.12
Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol (1998) 2.00
Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol (1997) 1.78
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol (1998) 1.38
Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron (2008) 1.37
A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation. Mol Biol Cell (1999) 1.28
Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer (2006) 1.25
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol (2002) 1.19
The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J Cell Biol (2001) 1.19
Intestinal epithelial restitution. Involvement of specific laminin isoforms and integrin laminin receptors in wound closure of a transformed model epithelium. Am J Pathol (1997) 1.17
Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest (2007) 1.17
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res (2010) 1.17
Pancreatic carcinomas deposit laminin-5, preferably adhere to laminin-5, and migrate on the newly deposited basement membrane. Am J Pathol (1997) 1.16
Defining the role of laminin-332 in carcinoma. Matrix Biol (2009) 1.14
Laminin-5 in epithelial tumour invasion. J Mol Histol (2004) 1.14
Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer (1999) 1.12
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Laminin-332-integrin interaction: a target for cancer therapy? Curr Med Chem (2008) 1.11
Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res (2006) 1.10
Differential expression of laminin 5 (alpha 3 beta 3 gamma 2) by human malignant and normal prostate. Am J Pathol (1996) 1.10
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer (2001) 1.09
Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. Head Face Med (2008) 1.08
Down-regulation of laminin-5 in breast carcinoma cells. Mol Med (1998) 1.07
A genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival. Clin Cancer Res (2009) 1.00
Laminin and collagen IV subunit distribution in normal and neoplastic tissues of colorectum and breast. Br J Cancer (1997) 1.00
Converging signals synergistically activate the LAMC2 promoter and lead to accumulation of the laminin gamma 2 chain in human colon carcinoma cells. Biochem J (2003) 0.97
Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity. Neoplasia (2004) 0.92
Laminin-5 is a biomarker of invasiveness in cervical adenocarcinoma. Diagn Pathol (2012) 0.92
Overexpression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation. Am J Pathol (2007) 0.92
Expression of laminin 5-γ2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion. Br J Cancer (2011) 0.91
Immunohistochemical expression of basement membrane proteins of verrucous carcinoma of the oral mucosa. Clin Oral Investig (2009) 0.90
Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion. Lab Invest (2013) 0.90
[Oral adenoid squemous carcinoma. Tumor markers and prognosis]. Mund Kiefer Gesichtschir (2004) 0.89
MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma. Am J Pathol (2012) 0.87
Mesenchymal cells contribute to the synthesis and deposition of the laminin-5 gamma2 chain in the invasive front of oral squamous cell carcinoma. J Mol Histol (2007) 0.87
Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). BMC Cancer (2008) 0.86
Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer. World J Gastroenterol (2009) 0.86
Laminin 5 gamma 2 chain expression: a marker of early invasiveness in colorectal adenomas. Mol Pathol (2003) 0.86
Hypoxic conditions induce a cancer-like phenotype in human breast epithelial cells. PLoS One (2012) 0.85
Progesterone receptor A-regulated gene expression in mammary organoid cultures. J Steroid Biochem Mol Biol (2009) 0.85
Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br J Pharmacol (2006) 0.84
Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front. Histochem Cell Biol (2005) 0.84
Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5gamma2 chain during colorectal carcinoma tumor progression. Virchows Arch (2004) 0.83
Expression of extracellular matrix proteins in cervical squamous cell carcinoma--a clinicopathological study. J Clin Pathol (1998) 0.82
Involvement of activator protein 1 complexes in the epithelium-specific activation of the laminin gamma2-chain gene promoter by hepatocyte growth factor (scatter factor). Biochem J (2000) 0.81
Clinicopathological significance of MMP-7, laminin γ2 and EGFR expression at the invasive front of gastric carcinoma. Gastric Cancer (2013) 0.80
Expressions of the γ2 chain of laminin-5 and secreted protein acidic and rich in cysteine in esophageal squamous cell carcinoma and their relation to prognosis. Chin J Cancer (2011) 0.79
Modulation of TGF-β-inducible hypermotility by EGF and other factors in human prostate epithelial cells and keratinocytes. In Vitro Cell Dev Biol Anim (2010) 0.79
Distribution of basement membrane anchoring molecules in normal and transformed endometrium: altered expression of laminin gamma2 chain and collagen type XVII in endometrial adenocarcinomas. J Mol Histol (2004) 0.78
Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Dig Dis Sci (2007) 0.78
RSK activation of translation factor eIF4B drives abnormal increases of laminin γ2 and MYC protein during neoplastic progression to squamous cell carcinoma. PLoS One (2013) 0.78
Amino-terminal fragments of laminin γ2 chain stimulate migration of metastatic breast cancer cells by interacting with CD44. Clin Exp Metastasis (2015) 0.77
Amino-terminal fragments of laminin γ2 chain retract vascular endothelial cells and increase vascular permeability. Cancer Sci (2014) 0.76
Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin γ2 chain. Cancer Sci (2016) 0.75
Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma. Cancer Sci (2015) 0.75
Prognostic significance of circulating laminin gamma2 for early-stage non-small-cell lung cancer. Onco Targets Ther (2016) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
Kalinin: an epithelium-specific basement membrane adhesion molecule that is a component of anchoring filaments. J Cell Biol (1991) 3.30
Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res (1981) 3.00
Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum (1993) 2.92
A new nomenclature for the laminins. Matrix Biol (1994) 2.82
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor. J Biol Chem (1992) 2.36
Human laminin B1 chain. A multidomain protein with gene (LAMB1) locus in the q22 region of chromosome 7. J Biol Chem (1987) 2.36
Molecular heterogeneity of basal laminae: isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere. J Cell Biol (1990) 2.33
Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol (1992) 2.17
Human laminin B2 chain. Comparison of the complete amino acid sequence with the B1 chain reveals variability in sequence homology between different structural domains. J Biol Chem (1988) 2.07
Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits. Cell Regul (1990) 2.02
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal assignment. J Cell Biol (1992) 1.84
Expression of integrins and basement membrane components by wound keratinocytes. J Clin Invest (1993) 1.80
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Mutations in the gamma 2 chain gene (LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bullosa. Nat Genet (1994) 1.65
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement for integrin receptors. J Cell Biol (1994) 1.41
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol (1991) 1.23
Monoclonal antibody GB3 defines a widespread defect of several basement membranes and a keratinocyte dysfunction in patients with lethal junctional epidermolysis bullosa. Lab Invest (1991) 1.23
The complete primary structure for a novel laminin chain, the laminin B1k chain. J Biol Chem (1994) 1.19
The 100-kDa chain of nicein/kalinin is a laminin B2 chain variant. Eur J Biochem (1994) 1.17
The laminin family. Curr Opin Cell Biol (1993) 1.17
Primary structure of the human laminin A chain. Limited expression in human tissues. Biochem J (1991) 1.16
The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol (1994) 1.11
Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res (1989) 1.06
Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem (1993) 1.00
Basement membrane collagen-IV synthesis in colorectal tumours. Int J Cancer (1992) 0.97
An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett (1993) 0.97
The basement membrane protein BM-600/nicein codistributes with kalinin and the integrin alpha 6 beta 4 in human cultured keratinocytes. Exp Cell Res (1993) 0.90
Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell (1998) 9.85
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry (1982) 6.87
Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 5.84
Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med (1996) 4.72
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science (1990) 4.15
The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet (2001) 4.00
Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A (1999) 3.77
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet (1995) 3.05
Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem (1993) 2.89
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol (2000) 2.87
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (1999) 2.62
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem (1991) 2.61
Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. Am J Hum Genet (1999) 2.44
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Human laminin B1 chain. A multidomain protein with gene (LAMB1) locus in the q22 region of chromosome 7. J Biol Chem (1987) 2.36
Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell (1995) 2.34
cDNA clones coding for the pro-alpha1(IV) chain of human type IV procollagen reveal an unusual homology of amino acid sequences in two halves of the carboxyl-terminal domain. J Biol Chem (1985) 2.30
Role of the scavenger receptor MARCO in alveolar macrophage binding of unopsonized environmental particles. J Exp Med (1999) 2.08
Human laminin B2 chain. Comparison of the complete amino acid sequence with the B1 chain reveals variability in sequence homology between different structural domains. J Biol Chem (1988) 2.07
Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. Proc Natl Acad Sci U S A (1990) 2.04
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology (1999) 1.97
High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol (1994) 1.96
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol (1998) 1.95
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res (1995) 1.93
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int (2006) 1.91
Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol (1990) 1.91
Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J (1989) 1.89
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol (1989) 1.85
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal assignment. J Cell Biol (1992) 1.84
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol (1987) 1.79
Nephrin is involved in podocyte maturation but not survival during glomerular development. Kidney Int (2007) 1.79
Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS (1999) 1.77
Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science (1993) 1.77
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res (1992) 1.71
Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J (1999) 1.69
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem (1991) 1.68
Structure of the human type IV collagenase gene. J Biol Chem (1990) 1.68
Mutations in the gamma 2 chain gene (LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bullosa. Nat Genet (1994) 1.65
Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int (2000) 1.65
Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol (1999) 1.65
Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol (1998) 1.64
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Herlitz's junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the gamma 2 subunit of nicein/kalinin (LAMININ-5). Nat Genet (1994) 1.63
Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing. J Invest Dermatol (1995) 1.60
Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med (1998) 1.57
Human laminin M chain (merosin): complete primary structure, chromosomal assignment, and expression of the M and A chain in human fetal tissues. J Cell Biol (1994) 1.57
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol (2001) 1.57
Biosynthesis of type IV procollagens. Biochemistry (1980) 1.57
High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol (1998) 1.57
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem (1992) 1.55
Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy. Br J Haematol (1993) 1.55
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol (2001) 1.51
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 1.51
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry (1981) 1.49
Lactational competence and involution of the mouse mammary gland require plasminogen. Development (2000) 1.48